Has nanotechnology led to improved therapeutic outcomes?

References

• Merisko-Liversidge EM, Liversidge GG. (2008). Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol Pathol, 36:43–48.
   PubMed Web of Science ®Google Scholar
• Yih TC, Al-Fandi M. (2006). Engineered nanoparticles as precise drug delivery systems. J Cell Biochem, 97:1184–1190.
   PubMed Web of Science ®Google Scholar
• Rao GC, Kumar MS, Mathivanan N, Rao ME. (2004). Nanosuspensions as the most promising approach in nanoparticulate drug delivery systems. Pharmazie, 59:5–9.
   PubMed Web of Science ®Google Scholar
• United States Patent and Trademark Office. (2010). Nanotechnology-Class Definition. [Online] Available at: http://www.uspto.gov/web/patents/classification/uspc977/defs977.htm. Accessed on 29 October 2010.
   Google Scholar
• Oberdörster G, Oberdörster E, Oberdörster J. (2005). Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect, 113:823–839.
   PubMed Web of Science ®Google Scholar
• Ferrari M. (2005). Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer, 5:161–171.
   PubMed Web of Science ®Google Scholar
• Hans ML, Lowman AM. (2002). Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mat Sci 6:319–327.
   Web of Science ®Google Scholar
• Dunne A, Devane J, O’Hara T. (1999). The relationship between in vitro drug dissolution and in vivo absorption. J R Stat Soc Ser D-Stat 48:125–133.
   Web of Science ®Google Scholar
• Amidon GL, Lennernäs H, Shah VP, Crison JR. (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res, 12:413–420.
   PubMed Web of Science ®Google Scholar
• FDA. (2000). Guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate release dosage forms based on a biopharmaceutical classification system. Center for Drug Evaluation and Research.
   Google Scholar
• Muller RH, Junghanns JAH. (2006). Drug nanocrystals/nanosuspensions for the delivery of poorly soluble drugs. In: Tochilin V (Ed.) Nanoparticulates as drug carriers. Imperial College Press, London, UK. 307–328.
   Google Scholar
• Fahr A, Liu X. (2007). Drug delivery strategies for poorly water-soluble drugs. Expert Opin Drug Deliv, 4:403–416.
   PubMed Web of Science ®Google Scholar
• Hilden LR, Morris KR. (2004). Physics of amorphous solids. J Pharm Sci, 93:3–12.
   PubMed Web of Science ®Google Scholar
• Tang B, Cheng G, Gu JC, Xu CH. (2008). Development of solid self-emulsifying drug delivery systems: preparation techniques and dosage forms. Drug Discov Today, 13:606–612.
   PubMed Web of Science ®Google Scholar
• Huang L, Dong J. (2008). Formulation strategies and practice used for candidates with water-insoluble properties for toxicology, biology, and pharmacology studies in discovery support. In: Liu R (Ed.) Water-insoluble drug formulation. CPR Press, Boca Raton, USA. 113–132.
   Google Scholar
• Noyes A, Whitney W. (1897). The rate of solution of solid substances in their own solutions, J Am Chem Soc 19: 930–934.
   Google Scholar
• Bisrat M, Nystrom C. (1988). Physicochemical aspects of drug release.8. the relation between particle-size and surface specific dissolution rate in agitated suspensions. Int J Pharm 47:223–231.
   Web of Science ®Google Scholar
• Mosharraf M, Nystrom C. (1995). The effect of particle-size and shape on the surface specific dissolution rate of microsized practically insoluble drugs. Int J Pharm 122:35–47.
   Web of Science ®Google Scholar
• Junghanns JU, Müller RH. (2008). Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine, 3:295–309.
   PubMed Web of Science ®Google Scholar
• Welling PG. (1977). Influence of food and diet on gastrointestinal drug absorption: a review. J Pharmacokinet Biopharm, 5:291–334.
   PubMedGoogle Scholar
• Gu CH, Li H, Levons J, Lentz K, Gandhi RB, Raghavan K et al. (2007). Predicting effect of food on extent of drug absorption based on physicochemical properties. Pharm Res, 24:1118–1130.
   PubMed Web of Science ®Google Scholar
• Welling PG. (1996). Effects of food on drug absorption. Annu Rev Nutr, 16:383–415.
   PubMed Web of Science ®Google Scholar
• Lentz KA. (2008). Current methods for predicting human food effect. AAPS J, 10:282–288.
   PubMed Web of Science ®Google Scholar
• Keck CM, Müller RH. (2006). Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm, 62:3–16.
   PubMed Web of Science ®Google Scholar
• Elan Drug Technologies. (2010). Nanocrystal® Technology. Commercialized Products. [Online] Available at: http://www.elandrugtechnologies.com/nanocrystal_technology/commercialised. Accessed on 17 October 2010.
   Google Scholar
• Merisko-Liversidge E, Liversidge GG, Cooper ER. (2003). Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci, 18:113–120.
   PubMed Web of Science ®Google Scholar
• Vazquez EM. (2000). Sirolimus: A new agent for prevention of renal allograft rejection. Am J Health-Syst Pharm 57:437–448.
   PubMed Web of Science ®Google Scholar
• Simamora P, Alvarez JM, Yalkowsky SH. (2001). Solubilization of rapamycin. Int J Pharm, 213:25–29.
   PubMed Web of Science ®Google Scholar
• Gandhi PJ, Murthy ZVP. (2010). Kinetic study of ultrasonic antisolvent crystallization of sirolimus. Cryst Res Technol 45:321–327.
   Web of Science ®Google Scholar
• Shen LJ, Wu FL. (2007). Nanomedicines in renal transplant rejection–focus on sirolimus. Int J Nanomedicine, 2:25–32.
   PubMed Web of Science ®Google Scholar
• Lampen A, Zhang Y, Hackbarth I, Benet LZ, Sewing KF, Christians U. (1998). Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. J Pharmacol Exp Ther, 285:1104–1112.
   PubMed Web of Science ®Google Scholar
• Zimmerman JJ, Ferron GM, Lim HK, Parker V. (1999). The effect of a high-fat meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin). J Clin Pharmacol, 39:1155–1161.
   PubMed Web of Science ®Google Scholar
• Mathew TH, Van Buren C, Kahan BD, Butt K, Hariharan S, Zimmerman JJ. (2006). A comparative study of sirolimus tablet versus oral solution for prophylaxis of acute renal allograft rejection. J Clin Pharmacol, 46:76–87.
   PubMed Web of Science ®Google Scholar
• Majumdar AK, Howard L, Goldberg MR, Hickey L, Constanzer M, Rothenberg PL et al. (2006). Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. J Clin Pharmacol, 46:291–300.
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R et al.; Aprepitant Protocol 052 Study Group. (2003). The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin–the Aprepitant Protocol 052 Study Group. J Clin Oncol, 21:4112–4119.
   PubMed Web of Science ®Google Scholar
• Wu Y, Loper A, Landis E, Hettrick L, Novak L, Lynn K et al. (2004). The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int J Pharm, 285:135–146.
   PubMed Web of Science ®Google Scholar
• Olver I, Shelukar S, Thompson KC. (2007). Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant. Int J Nanomedicine, 2:13–18.
   PubMed Web of Science ®Google Scholar
• Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A et al.; Aprepitant Protocol 054 Study Group. (2003). Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer, 97:3090–3098.
   PubMed Web of Science ®Google Scholar
• Tziomalos K, Athyros VG. (2006). Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review. Int J Nanomedicine, 1:129–147.
   PubMed Web of Science ®Google Scholar
• Guay DR. (1999). Micronized fenofibrate: a new fibric acid hypolipidemic agent. Ann Pharmacother, 33:1083–1103.
   PubMed Web of Science ®Google Scholar
• Guichard JP, Blouquin P, Qing Y. (2000). A new formulation of fenofibrate: suprabioavailable tablets. Curr Med Res Opin, 16:134–138.
   PubMed Web of Science ®Google Scholar
• Keating GM, Ormrod D. (2002). Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia. Drugs, 62:1909–1944.
   PubMed Web of Science ®Google Scholar
• Stamm A, Seth P. (2003). Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it. US Patent No. 6589552.
   Google Scholar
• Maciejewski S, Hilleman D. (2008). Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia. Pharmacotherapy, 28:570–575.
   PubMed Web of Science ®Google Scholar
• Femia RA, Goyette RE. (2005). The science of megestrol acetate delivery: potential to improve outcomes in cachexia. Biodrugs, 19:179–187.
   PubMed Web of Science ®Google Scholar
• Berenstein EG, Ortiz Z. (2005). Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev, CD004310.
   PubMed Web of Science ®Google Scholar
• Zhang ZB, Shen ZG, Wang JX, Zhao H, Chen JF, Yun J. (2009). Nanonization of megestrol acetate by liquid precipitation. Ind Eng Chem Res 48:8493–8499.
   Web of Science ®Google Scholar
• Hovey D, Pruitt J, Ryde T. (2005). Nanoparticulate megestrol formulations. US Patent Application. Pub.No. US 2005/0233001 A1.
   Google Scholar
• Graham KK, Mikolich DJ, Fisher AE, Posner MR, Dudley MN. (1994). Pharmacologic evaluation of megestrol acetate oral suspension in cachectic AIDS patients. J Acquir Immune Defic Syndr, 7:580–586.
   PubMed Web of Science ®Google Scholar
• Par Pharmaceuticals. Par Pharmaceuticals Announces FDA Approval of Megace ES for Anorexia, Cachexia, or an Unexplained, Significant Weight Loss in Patients with a Diagnosis of AIDS. [Online] Available at: http://www.parpharm.com/generics/index. Accessed on 19 October 2010.
   Google Scholar
• Deschamps B, Musaji N, Gillespie JA. (2009). Food effect on the bioavailability of two distinct formulations of megestrol acetate oral suspension. Int J Nanomedicine, 4:185–192.
   PubMed Web of Science ®Google Scholar
• Agu RU, Ugwoke MI, Armand M, Kinget R, Verbeke N. (2001). The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res, 2:198–209.
   PubMed Web of Science ®Google Scholar
• Suarez S, Hickey AJ. (2000). Drug properties affecting aerosol behavior. Respir Care, 45:652–666.
   PubMedGoogle Scholar
• Gehr P, Bachofen M, Weibel ER. (1978). The normal human lung: ultrastructure and morphometric estimation of diffusion capacity. Respir Physiol, 32:121–140.
   PubMedGoogle Scholar
• Laube BL. (2005). The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. Respir Care, 50:1161–1176.
   PubMedGoogle Scholar
• Sweeney TD, Brain JD. (1991). Pulmonary deposition: determinants and measurement techniques. Toxicol Pathol, 19:384–397.
   PubMed Web of Science ®Google Scholar
• Courrier HM, Butz N, Vandamme TF. (2002). Pulmonary drug delivery systems: recent developments and prospects. Crit Rev Ther Drug Carrier Syst, 19:425–498.
   PubMed Web of Science ®Google Scholar
• Labiris NR, Dolovich MB. (2003). Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol, 56:588–599.
   PubMed Web of Science ®Google Scholar
• Byron PR. (1986). Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J Pharm Sci, 75:433–438.
   PubMed Web of Science ®Google Scholar
• Jaques PA, Kim CS. (2000). Measurement of total lung deposition of inhaled ultrafine particles in healthy men and women. Inhal Toxicol, 12:715–731.
   PubMed Web of Science ®Google Scholar
• Henning A, Hein S, Schneider M, Bur M, Lehr CM. (2010). Pulmonary drug delivery: medicines for inhalation. In: Schaefer-Korting M (Ed.) Drug delivery. Springer, Berlin, Heidelberg, Germany. 176.
   Google Scholar
• Tsapis N, Bennett D, Jackson B, Weitz DA, Edwards DA. (2002). Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci USA, 99:12001–12005.
   PubMed Web of Science ®Google Scholar
• Sham JO, Zhang Y, Finlay WH, Roa WH, Löbenberg R. (2004). Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. Int J Pharm, 269:457–467.
   PubMed Web of Science ®Google Scholar
• Hadinoto K, Phanapavudhikul P, Kewu Z, Tan RBH. (2006). Novel formulation of large hollow nanoparticles aggregates as potential carriers in inhaled delivery of nanoparticulate drugs. Ind Eng Chem Res 45:3697–3706.
   Web of Science ®Google Scholar
• Hadinoto K, Zhu K, Tan RB. (2007). Drug release study of large hollow nanoparticulate aggregates carrier particles for pulmonary delivery. Int J Pharm, 341:195–206.
   PubMed Web of Science ®Google Scholar
• Hofmann W, Asgharian B. (2003). The effect of lung structure on mucociliary clearance and particle retention in human and rat lungs. Toxicol Sci, 73:448–456.
   PubMed Web of Science ®Google Scholar
• Schürch S, Gehr P, Im Hof V, Geiser M, Green F. (1990). Surfactant displaces particles toward the epithelium in airways and alveoli. Respir Physiol, 80:17–32.
   PubMedGoogle Scholar
• Geiser M. (2010). Update on macrophage clearance of inhaled micro- and nanoparticles. J Aerosol Med Pulm Drug Deliv, 23:207–217.
   PubMed Web of Science ®Google Scholar
• Takenaka S, Karg E, Kreyling WG, Lentner B, Möller W, Behnke-Semmler M et al. (2006). Distribution pattern of inhaled ultrafine gold particles in the rat lung. Inhal Toxicol, 18:733–740.
   PubMed Web of Science ®Google Scholar
• Semmler-Behnke M, Takenaka S, Fertsch S, Wenk A, Seitz J, Mayer P et al. (2007). Efficient elimination of inhaled nanoparticles from the alveolar region: evidence for interstitial uptake and subsequent reentrainment onto airways epithelium. Environ Health Perspect, 115:728–733.
   PubMed Web of Science ®Google Scholar
• Geiser M, Casaulta M, Kupferschmid B, Schulz H, Semmler-Behnke M, Kreyling W. (2008). The role of macrophages in the clearance of inhaled ultrafine titanium dioxide particles. Am J Respir Cell Mol Biol, 38:371–376.
   PubMed Web of Science ®Google Scholar
• Hoeben BJ, Burgess DS, McConville JT, Najvar LK, Talbert RL, Peters JI et al. (2006). In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis. Antimicrob Agents Chemother, 50:1552–1554.
   PubMed Web of Science ®Google Scholar
• McConville JT, Overhoff KA, Sinswat P, Vaughn JM, Frei BL, Burgess DS et al. (2006). Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model. Pharm Res, 23:901–911.
   PubMed Web of Science ®Google Scholar
• Vaughn JM, McConville JT, Burgess D, Peters JI, Johnston KP, Talbert RL et al. (2006). Single dose and multiple dose studies of itraconazole nanoparticles. Eur J Pharm Biopharm, 63:95–102.
   PubMed Web of Science ®Google Scholar
• Vaughn JM, Wiederhold NP, McConville JT, Coalson JJ, Talbert RL, Burgess DS et al. (2007). Murine airway histology and intracellular uptake of inhaled amorphous itraconazole. Int J Pharm, 338:219–224.
   PubMed Web of Science ®Google Scholar
• Garbuzenko OB, Saad M, Pozharov VP, Reuhl KR, Mainelis G, Minko T. (2010). Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance. Proc Natl Acad Sci USA, 107:10737–10742.
   PubMed Web of Science ®Google Scholar
• Brigger I, Dubernet C, Couvreur P. (2002). Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev, 54:631–651.
   PubMed Web of Science ®Google Scholar
• Hitzman CJ, Wattenberg LW, Wiedmann TS. (2006). Pharmacokinetics of 5-fluorouracil in the hamster following inhalation delivery of lipid-coated nanoparticles. J Pharm Sci, 95:1196–1211.
   PubMed Web of Science ®Google Scholar
• Azarmi S, Tao X, Chen H, Wang Z, Finlay WH, Löbenberg R et al. (2006). Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles. Int J Pharm, 319:155–161.
   PubMed Web of Science ®Google Scholar
• Sharma S, White D, Imondi AR, Placke ME, Vail DM, Kris MG. (2001). Development of inhalational agents for oncologic use. J Clin Oncol, 19:1839–1847.
   PubMed Web of Science ®Google Scholar
• Otterson GA, Villalona-Calero MA, Sharma S, Kris MG, Imondi A, Gerber M et al. (2007). Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs. Clin Cancer Res, 13:1246–1252.
   PubMed Web of Science ®Google Scholar
• Kraft WK, Steiger B, Beussink D, Quiring JN, Fitzgerald N, Greenberg HE et al. (2004). The pharmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteers. J Clin Pharmacol, 44:67–72.
   PubMed Web of Science ®Google Scholar
• Sung JC, Pulliam BL, Edwards DA. (2007). Nanoparticles for drug delivery to the lungs. Trends Biotechnol, 25:563–570.
   PubMed Web of Science ®Google Scholar
• Chono S, Tanino T, Seki T, Morimoto K. (2007). Uptake characteristics of liposomes by rat alveolar macrophages: influence of particle size and surface mannose modification. J Pharm Pharmacol, 59:75–80.
   PubMed Web of Science ®Google Scholar
• du Toit LC, Pillay V, Danckwerts MP. (2006). Tuberculosis chemotherapy: current drug delivery approaches. Respir Res, 7:118.
   PubMed Web of Science ®Google Scholar
• Pandey R, Sharma A, Zahoor A, Sharma S, Khuller GK, Prasad B. (2003). Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother, 52:981–986.
   PubMed Web of Science ®Google Scholar
• Sharma A, Sharma S, Khuller GK. (2004). Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J Antimicrob Chemother, 54:761–766.
   PubMed Web of Science ®Google Scholar
• Pandey R, Khuller GK. (2005). Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis (Edinb), 85:227–234.
   PubMed Web of Science ®Google Scholar
• Müller RH, Mäder K, Gohla S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm, 50:161–177.
   PubMed Web of Science ®Google Scholar
• Mansour HM, Rhee YS, Wu X. (2009). Nanomedicine in pulmonary delivery. Int J Nanomedicine, 4:299–319.
   PubMed Web of Science ®Google Scholar
• Pandey R, Khuller GK. (2005). Antitubercular inhaled therapy: opportunities, progress and challenges. J Antimicrob Chemother, 55:430–435.
   PubMed Web of Science ®Google Scholar
• Kawashima Y, Yamamoto H, Takeuchi H, Fujioka S, Hino T. (1999). Pulmonary delivery of insulin with nebulized DL-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect. J Control Release, 62:279–287.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Shen Z, Nagai T. (2001). Prolonged hypoglycemic effect of insulin-loaded polybutylcyanoacrylate nanoparticles after pulmonary administration to normal rats. Int J Pharm, 218:75–80.
   PubMed Web of Science ®Google Scholar
• Renwick LC, Brown D, Clouter A, Donaldson K. (2004). Increased inflammation and altered macrophage chemotactic responses caused by two ultrafine particle types. Occup Environ Med, 61:442–447.
   PubMed Web of Science ®Google Scholar
• Oberdörster G. (1997). Pulmonary carcinogenicity of inhaled particles and the maximum tolerated dose. Environ Health Perspect, 105 Suppl 5:1347–1355.
   PubMedGoogle Scholar
• Oberdörster G, Ferin J, Gelein R, Soderholm SC, Finkelstein J. (1992). Role of the alveolar macrophage in lung injury: studies with ultrafine particles. Environ Health Perspect, 97:193–199.
   PubMed Web of Science ®Google Scholar
• Renwick LC, Donaldson K, Clouter A. (2001). Impairment of alveolar macrophage phagocytosis by ultrafine particles. Toxicol Appl Pharmacol, 172:119–127.
   PubMed Web of Science ®Google Scholar
• Donaldson K, Stone V, Clouter A, Renwick L, MacNee W. (2001). Ultrafine particles. Occup Environ Med, 58:211–6, 199.
   Web of Science ®Google Scholar
• Nikula KJ. (2000). Rat lung tumors induced by exposure to selected poorly soluble nonfibrous particles. Inhal Toxicol, 12:97–119.
   PubMed Web of Science ®Google Scholar
• Borm PJ, Schins RP, Albrecht C. (2004). Inhaled particles and lung cancer, part B: paradigms and risk assessment. Int J Cancer, 110:3–14.
   PubMed Web of Science ®Google Scholar
• Driscoll KE, Deyo LC, Carter JM, Howard BW, Hassenbein DG, Bertram TA. (1997). Effects of particle exposure and particle-elicited inflammatory cells on mutation in rat alveolar epithelial cells. Carcinogenesis, 18:423–430.
   PubMed Web of Science ®Google Scholar
• Mühlfeld C, Gehr P, Rothen-Rutishauser B. (2008). Translocation and cellular entering mechanisms of nanoparticles in the respiratory tract. Swiss Med Wkly, 138:387–391.
   PubMed Web of Science ®Google Scholar
• Turco SJ. (2006). Intravenous admixtures. In: Troy BD (ed.) Remington: the science and practice of pharmacy. Lippincott Williams & Wilkins, Maryland, USA.
   Google Scholar
• Shi Y, Porter W, Merdan T, Li LC. (2009). Recent advances in intravenous delivery of poorly water-soluble compounds. Expert Opin Drug Deliv, 6:1261–1282.
   PubMed Web of Science ®Google Scholar
• Akers, MJ. (2006). Parenteral preparations. In: Troy, BD (ed.) Remington: the science and practice of pharmacy. Lippincott Williams & Wilkins, Maryland, USA.
   Google Scholar
• Yalkowsky SH, Krzyzaniak JF, Ward GH. (1998). Formulation-related problems associated with intravenous drug delivery. J Pharm Sci, 87:787–796.
   PubMed Web of Science ®Google Scholar
• Wong J, Brugger A, Khare A, Chaubal M, Papadopoulos P, Rabinow B et al. (2008). Suspensions for intravenous (IV) injection: a review of development, preclinical and clinical aspects. Adv Drug Deliv Rev, 60:939–954.
   PubMed Web of Science ®Google Scholar
• United State Pharmacopeia (USP). The National Formulary. (2007). Particulate matter in injections.
   Google Scholar
• Rabinow BE. (2004). Nanosuspensions in drug delivery. Nat Rev Drug Discov, 3:785–796.
   PubMed Web of Science ®Google Scholar
• Haley B, Frenkel E. (2008). Nanoparticles for drug delivery in cancer treatment. Urol Oncol, 26:57–64.
   PubMed Web of Science ®Google Scholar
• Storm G, Belliot SO, Daemen T, Lasic DD. (1995). Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev 17:31–48.
   Web of Science ®Google Scholar
• Cho K, Wang X, Nie S, Chen ZG, Shin DM. (2008). Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res, 14:1310–1316.
   PubMed Web of Science ®Google Scholar
• Davis ME, Chen ZG, Shin DM. (2008). Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov, 7:771–782.
   PubMed Web of Science ®Google Scholar
• Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW et al. (2006). Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA, 103:6315–6320.
   PubMed Web of Science ®Google Scholar
• Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. (2007). Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA, 104:15549–15554.
   PubMed Web of Science ®Google Scholar
• Vauthier C, Dubernet C, Chauvierre C, Brigger I, Couvreur P. (2003). Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles. J Control Release, 93:151–160.
   PubMed Web of Science ®Google Scholar
• Schluep T, Hwang J, Cheng J, Heidel JD, Bartlett DW, Hollister B et al. (2006). Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin Cancer Res, 12:1606–1614.
   PubMed Web of Science ®Google Scholar
• Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E et al. (2002). Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res, 8:1038–1044.
   PubMed Web of Science ®Google Scholar
• Desai NP, Soon-Shiong P, Yang, A. (2007). Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use therof. US Patent No. 0092563.
   Google Scholar
• Desai NP, Selvaraj R, Yang A, Soon-Shiong P. (2010). Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents. US Patent No. 7771751.
   Google Scholar
• Desai N, Trieu V, Damascelli B, Soon-Shiong P. (2009). SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients. Transl Oncol, 2:59–64.
   PubMed Web of Science ®Google Scholar
• Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A et al. (2006). Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res, 12:1317–1324.
   PubMed Web of Science ®Google Scholar
• Cortes J, Saura C. (2010). Nanoparticle albumin-bound (nab (TM))-paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer. EJC Suppl 8:1–10.
   Web of Science ®Google Scholar
• ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. (2003). Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet, 42:665–685.
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P et al. (2005). Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol, 23:7794–7803.
   PubMed Web of Science ®Google Scholar